Tag: LLP

PITTSBURGH, Aug. 11, 2025 (GLOBE NEWSWIRE) -- PhyNet Dermatology LLC (“PhyNet”) recently announced a cybersecurity incident involving its affiliate Total Vein & Skin, LLC d/b/a Premier Dermatology Partners (“TVS”), which impacted the personal information of an unknown number of individuals.¹ The information potentially impacted in the data breach includes individuals’ names, addresses, Social Security number, financial account information, date of birth, medical history information, treatment information, diagnosis information, treating physician, medical record number, and health insurance information.

PLEASE CLICK HERE TO SUBMIT YOUR CONTACT INFORMATION

Strategic acquisition strengthens North America retail presence and operating model, expands Intermex beyond its historically high growth Latin America corridors, and is expected to accelerate digital new customer acquisition

SAN DIEGO, Aug. 10, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Lineage, Inc. (NASDAQ: LINE) common stock in or traceable to the registration statement used in connection with Lineage’s July 2024 initial public offering (the “IPO”), have until September 30, 2025 to seek appointment as lead plaintiff of the Lineage class action lawsuit. Captioned City of St. Clair Shores Police and Fire Retirement System v. Lineage, Inc., No. 25-cv-12383 (E.D. Mich.), the Lineage class action lawsuit charges Lineage as well as certain of its top executives, directors, IPO underwriters, and IPO sponsor with violations of the Securities Act of 1933.

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Inspire Medical Systems, Inc. (“Inspire” or the “Company”) (NYSE: INSP).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Groupon, Inc. (“Groupon” or the “Company”) (NASDAQ: GRPN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  agilon health, Inc. (“agilon” or the “Company”) (NYSE: AGL).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Altimmune, Inc.  (“Altimmune” or the “Company”) (NASDAQ: ALT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Designer Brands Inc.  (“Designer Brands” or the “Company”) (NYSE: DBI).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  argenx SE (“argenx” or the “Company”) (NASDAQ: ARGX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Dyne Therapeutics, Inc. (“Dyne” or the “Company”) (NASDAQ: DYN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. (“Edgewise” or the “Company”) (NASDAQ: EWTX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.